Fusion protein containing trail and IgG binding domain and the uses thereof
US11952402B2 · kind B2 · utility
0Cited by
0References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 10, 2020 |
| Grant date | Apr 9, 2024 |
| Priority date | — |
| Expiry date | Sep 1, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12R2001/19
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A recombinant protein includes a TRAIL domain and an IgG binding domain IgBD. In the recombinant protein, IgBD can be fused at the N-terminus or C-terminus of the TRAIL domain. The anti-tumor effect of the recombinant protein after binding to endogenous or exogenous IgG is significantly stronger than that of TRAIL, and can be used in the treatment of cell proliferative diseases with high expression of death receptors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.